These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11316962)

  • 1. Relationship between subjective cognitive symptoms and frontal executive abilities in chronic schizophrenic outpatients.
    Zanello A; Huguelet P
    Psychopathology; 2001; 34(3):153-8. PubMed ID: 11316962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
    Semkovska M; Bédard MA; Stip E
    Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific cognitive flexibility rehabilitation in schizophrenia.
    Delahunty A; Morice R; Frost B
    Psychol Med; 1993 Feb; 23(1):221-7. PubMed ID: 8097331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective cognitive dysfunction in first-episode and chronic schizophrenic patients.
    Moritz S; Lambert M; Andresen B; Böthern A; Naber D; Krausz M
    Compr Psychiatry; 2001; 42(3):213-6. PubMed ID: 11349240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could the hypofrontality pattern in schizophrenia be modified through neuropsychological rehabilitation?
    Penadés R; Boget T; Lomeña F; Mateos JJ; Catalán R; Gastó C; Salamero M
    Acta Psychiatr Scand; 2002 Mar; 105(3):202-8. PubMed ID: 11939974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function.
    Velligan DI; Ritch JL; Sui D; DiCocco M; Huntzinger CD
    Psychiatry Res; 2002 Dec; 113(3):227-36. PubMed ID: 12559479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
    Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
    Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive deficits and psychopathology in institutionalized versus community-dwelling elderly schizophrenia patients.
    Evans JD; Negron AE; Palmer BW; Paulsen JS; Heaton RK; Jeste DV
    J Geriatr Psychiatry Neurol; 1999; 12(1):11-5. PubMed ID: 10447149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia.
    Scully PJ; Coakley G; Kinsella A; Waddington JL
    Psychol Med; 1997 Nov; 27(6):1303-10. PubMed ID: 9403902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is executive impairment associated with schizophrenic syndromes? A meta-analysis.
    Dibben CR; Rice C; Laws K; McKenna PJ
    Psychol Med; 2009 Mar; 39(3):381-92. PubMed ID: 18588741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients.
    Comparelli A; De Carolis A; Corigliano V; Romano S; Kotzalidis G; Brugnoli R; Tamorri S; Curto M; Tatarelli R; Ferracuti S; Girardi P
    Compr Psychiatry; 2012 Oct; 53(7):931-9. PubMed ID: 22444951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients.
    Gharaeipour M; Scott BJ
    Schizophr Res; 2012 Dec; 142(1-3):165-70. PubMed ID: 23102691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
    Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
    Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
    Krausz M; Moritz S; Lambert M; Naber D
    Int Clin Psychopharmacol; 2000 Mar; 15(2):77-81. PubMed ID: 10759338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.